Amgen's earnings call highlights continued revenue growth, though with a notable Aranesp decline impacting overall performance.  Management confidently projects 2009 guidance, emphasizing investments in Denosumab and pipeline development, while aiming for continued cost efficiencies.  The call's tone suggests a cautious but optimistic outlook, focusing on the potential of Denosumab's market entrance and managing the impact of biosimilars.
[1]
